Search Result
Results for "
LRRK2
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-111493
-
-
-
- HY-RS07833
-
|
Small Interfering RNA (siRNA)
|
Others
|
LRRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for LRRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
LRRK2 Human Pre-designed siRNA Set A
LRRK2 Human Pre-designed siRNA Set A
-
- HY-RS07834
-
|
Small Interfering RNA (siRNA)
|
Others
|
Lrrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Lrrk2 Mouse Pre-designed siRNA Set A
Lrrk2 Mouse Pre-designed siRNA Set A
-
- HY-RS07835
-
|
Small Interfering RNA (siRNA)
|
Others
|
Lrrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Lrrk2 Rat Pre-designed siRNA Set A
Lrrk2 Rat Pre-designed siRNA Set A
-
- HY-153058
-
|
LRRK2
JAK
AMPK
|
Neurological Disease
Cancer
|
LRRK2-IN-8 is a LRRK2 inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC50s lower than 10 nM, and inhibits TYK2 and NUAK1 with IC50s of 10-100 nM .
|
-
-
- HY-151441
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier .
|
-
-
- HY-151444
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier .
|
-
-
- HY-152107
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes .
|
-
-
- HY-10875
-
-
-
- HY-145317
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-2 (compoubd 22) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of <0.6 nM. LRRK2-IN-2 can be used for the research of Parkinson's disease .
|
-
-
- HY-145318
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-3 (compoubd 24) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of 2.6 nM in human PBMCs. LRRK2-IN-3 can be used for the research of Parkinson's disease .
|
-
-
- HY-156167
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-10 (compound 34) is a potent, mutation-selective, and brain penetrant G2019S-LRRK2 kinase inhibitor with IC50s of 11 nM and 5.2 nM for G2019S-LRRK2 pS935 and G2019S-LRRK2 pS1292, respectively. LRRK2-IN-10 has the potential for Parkinson's disease research .
|
-
-
- HY-144074
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .
|
-
-
- HY-153103
-
|
LRRK2
JAK
AMPK
|
Inflammation/Immunology
|
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC50 values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research .
|
-
-
- HY-152107A
-
|
LRRK2
|
Neurological Disease
|
(R,R)-LRRK2-IN-7 is the isomer of LRRK2-IN-7 (HY-152107). LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.
|
-
-
- HY-B0792
-
|
LRRK2
|
Neurological Disease
|
CZC-54252 is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC50 of ~1 nM. CZC-54252 has a neuroprotective activity .
|
-
-
- HY-B0792A
-
|
LRRK2
|
Neurological Disease
|
CZC-54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC50 of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity .
|
-
-
- HY-112855
-
|
LRRK2
|
Neurological Disease
|
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .
|
-
-
- HY-15800A
-
|
LRRK2
|
Neurological Disease
Inflammation/Immunology
|
CZC-25146 is a potent and orally active LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases [2] .
|
-
-
- HY-15800
-
|
LRRK2
|
Neurological Disease
Inflammation/Immunology
|
CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases [2] .
|
-
-
- HY-12282
-
|
LRRK2
|
Neurological Disease
|
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .
|
-
-
- HY-155150
-
|
LRRK2
PROTACs
|
Cancer
|
JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD)?research .
|
-
-
- HY-148030
-
|
PROTACs
LRRK2
|
Neurological Disease
|
XL01126 is a potent degrader of LRRK2 with DC50s of 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2), respectively. XL01126 can cross blood-brain barrier and be used as a degrader probe in Parkinson’s disease research. XL01126 exerts function of study of non-catalytic and scaffolding functions of LRRK2 .
|
-
-
- HY-16936
-
|
|
|
JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC50s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .
|
-
-
- HY-108886
-
JWG-071
1 Publications Verification
|
ERK
|
Cancer
|
JWG-071 is the kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC50 values of 88nM and 109 nM, respectively .
|
-
-
- HY-156429
-
|
LRRK2
|
Neurological Disease
|
MK-1468 is a high selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 0.8 nM. MK-1468 can be used in study Parkinson’s disease .
|
-
-
- HY-13237
-
-
-
- HY-13488
-
|
LRRK2
MNK
|
Neurological Disease
|
HG-10-102-01 is a highly potent, selective, and brain-penetrable LRRK2 inhibitor, with IC50 values of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2 and MLK1, with IC50 values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research [2].
|
-
-
- HY-18163
-
-
-
- HY-18163A
-
|
LRRK2
|
Neurological Disease
|
GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM.
|
-
-
- HY-12477
-
|
LRRK2
|
Neurological Disease
|
PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC50 of 3 nM.
|
-
-
- HY-134562
-
-
-
- HY-142647
-
-
-
- HY-14403
-
|
ERK
|
Cancer
|
ERK5-IN-1 is a potent ERK5 inhibitor with an IC50 of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC50 of 26 nM.
|
-
-
- HY-15796
-
GNE0877
2 Publications Verification
|
LRRK2
|
Neurological Disease
|
GNE0877 is a highly selective, orally active and brain-penetrant LRRK2 inhibitor with an IC50 of 3 nM and a Ki of 0.7 nM. GNE0877 can be used for the research of neuroscience .
|
-
-
- HY-100411
-
MLi-2
4 Publications Verification
|
LRRK2
|
Neurological Disease
|
MLi-2 is an orally active and highly selective LRRK2 inhibitor with an IC50 of 0.76 nM. MLi-2 has the potential for Parkinson’s disease .
|
-
-
- HY-120085
-
PFE-360
2 Publications Verification
PF-06685360
|
LRRK2
|
Neurological Disease
|
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC50 of 2.3 nM in vivo [2].
|
-
-
- HY-13687
-
IKK 16
Maximum Cited Publications
16 Publications Verification
|
IKK
LRRK2
|
Inflammation/Immunology
|
IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC50s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC50 of 50 nM.
|
-
-
- HY-148353
-
|
LRRK2
|
Neurological Disease
|
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC50 value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) [2].
|
-
-
- HY-13687A
-
|
IKK
LRRK2
|
Inflammation/Immunology
|
IKK 16 hydrochloride is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC50s of 40 nM, 70 nM and 200 nM, respectively . IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC50 of 50 nM [2].
|
-
-
- HY-112809
-
|
Syk
Src
LRRK2
GSK-3
JAK
VEGFR
Aurora Kinase
|
Inflammation/Immunology
|
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .
|
-
-
- HY-163184
-
|
Ser/Thr Protease
|
Cancer
|
DCLK1-IN-3 is a potent and selective doublecortin-like kinase 1 (DCLK1) inhibitor with an IC50 of 47 nM. DCLK1-IN-3 can be used for the research of cancer .
|
-
-
- HY-163185
-
|
Ser/Thr Protease
|
Cancer
|
DCLK1-IN-4 (compound D2) is a potent and selective doublecortin-like kinase 1 (DCLK1) inhibitor with an IC50 of 70 nM. DCLK1-IN-4 can be used for the research of cancer .
|
-
-
-
HY-L029
-
|
1371 compounds
|
Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease.
MCE provides a unique collection of 1371 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.
|
-
-
HY-L085
-
|
1339 compounds
|
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.
MCE offers a unique collection of 1339 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.
|
-
-
HY-L086
-
|
2228 compounds
|
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.
MCE offers a unique collection of 2228 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.
|
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P83076
-
AURA17; Dardarin antibody; ; Leucine rich repeat kinase 2; LRRK 2 antibody; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2
|
WB, IHC-P, ICC/IF
|
Human, Mouse |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: